Improvements in antiretroviral therapy outcomes over calendar timeBoyd, Mark ACurrent Opinion in HIV and AIDS: May 2009 - Volume 4 - Issue 3 - p 194–199 doi: 10.1097/COH.0b013e328329fc8d Early treatment: Edited by Sean Emery and Andrew Phillips Abstract Author Information Purpose of review The introduction of combination antiretroviral therapy (cART) led to substantial reductions in HIV-associated morbidity and mortality. However, the regimens in the early cART era were cumbersome and toxic. The introduction of new ART agents, fixed-dose combinations and novel strategies for cART delivery such as ritonavir ‘boosting’ of HIV-protease inhibitors have led to a perception of improvements in the tolerability and durability of contemporary cART regimens. It is in turn assumed that these developments have led to improved outcomes in the latter era of cART. Recent findings Both cohort studies and randomized clinical trials suggest improvements in cART outcomes over calendar time. Key associated factors include reduced pill burden and dosing interval and improved tolerability and reduced toxicity of newer ART. A critical appreciation of the association between ART adherence and regimen durability has been important. Cohorts in recent times have included more patients who are completely ART-naïve at therapy initiation. Summary The prognosis of HIV infection in developed countries is in the order of 40 years after cART initiation. An appreciation of the factors associated with long-term control of HIV viraemia is essential for the optimal management of the HIV-infected individual in contemporary practice. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia Correspondence to Mark A. Boyd, MD, FRACP, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Sydney, NSW 2010, Australia Tel: +61 2 9385 0900; fax: +61 2 9385 0910; e-mail: firstname.lastname@example.org © 2009 Lippincott Williams & Wilkins, Inc.